Supplementary Data from Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition

Abstract

<p>Figure S1. Evaluation of the KIT locus in GIST cell lines. Figure S2. Effect of imatinib and JQ1 treatment on cell cycle and apoptosis in GIST cell lines. Figure S3. Effect of JQ1 and imatinib on KIT mRNA, protein and signaling. Figure S4. KIT rescue with enhancer independence in GIST430 and effects of HAND1 overexpression on KIT levels and drug sensitivity. Figure S5. Differences in GIST cell line enhancers and effects of drug treatment at the KIT locus in GIST430. Figure S6. H3K27ac ChIP-seq signal and RNA expression changes of exemplary genes following imatinib and/or JQ1 treatment in GIST. Figure S7. Expression and dependency of genes at the KIT locus in GIST cells. Figure S8. Combinatorial effects of bromodomain and KIT inhibition. Figure S9. Consequences of bromodomain inhibition in GIST xenograft models. Table S1. Oligonucleotide Sequences. Table S2. IC50 values in GIST cell lines.</p>